Alpha-Ketoglutarate: The Metabolite That Reversed 8 Years of Biological Aging

A naturally occurring molecule in your body might be the most underrated longevity supplement on the market. Calcium alpha-ketoglutarate (Ca-AKG) — a stabilized form of a key metabolite in the Krebs cycle — has shown remarkable results in clinical trials, reducing biological age by an average of eight years in just seven months.

What Is Alpha-Ketoglutarate?

Alpha-ketoglutarate (AKG) is not some exotic compound discovered in a rainforest. It's a molecule your body already makes — a critical intermediate in the citric acid cycle (Krebs cycle), the metabolic engine that converts food into cellular energy.

AKG plays multiple roles beyond energy production:

• Nitrogen metabolism — helps recycle amino acids and remove ammonia
• Collagen synthesis — acts as a cofactor for prolyl hydroxylases, the enzymes that stabilize collagen
• Epigenetic regulation — serves as a cofactor for TET enzymes, which demethylate DNA and influence gene expression
• Stem cell maintenance — supports the self-renewal capacity of pluripotent stem cells

The problem? AKG levels decline significantly with age. Plasma concentrations drop by up to tenfold between ages 40 and 80. This decline correlates with many hallmarks of aging — from increased inflammation to impaired mitochondrial function.

The Clinical Evidence

The Rejuvant Study: 8 Years Younger in 7 Months

The most striking human data comes from a study published in Aging (2021), where 42 participants (28 men, 14 women) took a timed-release formulation of calcium alpha-ketoglutarate combined with vitamins A (for men) or D (for women) for an average of seven months.

The results were remarkable:

• 40 out of 42 participants showed a decrease in biological age
• Average biological age reduction: 7.96 years
• Males: 8.44 years average reduction
• Females: 6.98 years average reduction
• Biological age was measured using DNA methylation patterns (TruAge epigenetic test)

The study was retrospective and lacked a placebo control — important limitations. But the magnitude and consistency of the effect (95% of participants responded) caught the attention of the longevity research community.

The ABLE Study: A Rigorous Follow-Up

To address the limitations of the Rejuvant study, the ABLE trial (Alpha-ketoglutarate supplementation lowers Biological agE) was launched — a proper double-blinded, placebo-controlled, randomized clinical trial based in Singapore.

Study design:

• 120 healthy participants aged 40–60
• 1 gram of sustained-release Ca-AKG daily vs. placebo
• 6 months of supplementation + 3-month follow-up
• Primary endpoint: change in DNA methylation age

Led by Professor Brian Kennedy at the National University of Singapore, the ABLE study is measuring not just epigenetic age but also:

• Inflammatory markers (CRP, IL-6)
• Metabolic parameters (glucose, lipids)
• Physical performance (grip strength, leg extension)
• Cardiovascular health (arterial stiffness)
• Skin aging (autofluorescence)

Results are expected by late 2025 and could either validate or temper the enthusiasm from earlier findings.

The 2024 Confirmatory Trial

A separate 2024 trial with 42 healthy adults aged 40–65 confirmed earlier findings — Ca-AKG supplementation produced significant reductions in biomarkers associated with:

• Inflammation (lower CRP and pro-inflammatory cytokines)
• Oxidative stress (improved antioxidant capacity)
• Cellular senescence (reduced senescence-associated markers)

The biological age reduction in the supplemented group averaged 8 years compared to no change in placebo.

How Does AKG Reverse Aging?

The mechanisms are multifaceted and surprisingly well-understood:

1. Epigenetic Rejuvenation

AKG is a required cofactor for TET (ten-eleven translocation) enzymes, which remove methyl groups from DNA. As we age, aberrant DNA methylation patterns accumulate — essentially "noise" that disrupts gene expression. By supporting TET enzyme function, AKG helps maintain cleaner epigenetic patterns.

2. Inflammation Suppression

AKG inhibits the NF-κB signaling pathway, a master regulator of inflammation. Chronic low-grade inflammation ("inflammaging") is a hallmark of aging. In animal studies, AKG supplementation reduced inflammatory cytokines by 40–60%.

3. Mitochondrial Support

As a direct substrate of the Krebs cycle, AKG supports mitochondrial energy production. In aged mice, AKG supplementation restored mitochondrial membrane potential and ATP output to near-youthful levels.

4. Senescence Delay

AKG appears to delay cellular senescence — the state where cells stop dividing but refuse to die, instead secreting harmful inflammatory molecules. In cell culture studies, AKG treatment reduced senescence markers and extended replicative lifespan.

5. Stem Cell Protection

AKG maintains the epigenetic landscape of stem cells, supporting their ability to self-renew and differentiate properly. This could explain its broad-spectrum anti-aging effects — healthy stem cells mean better tissue repair throughout the body.

Animal Evidence: Longer, Healthier Lives

The animal data is extensive and consistent:

• C. elegans (worms): AKG extended lifespan by ~50% through mechanisms involving ATP synthase and the TOR pathway
• Drosophila (flies): Lifespan extension of 10–15% with AKG supplementation
• Mice: A landmark 2020 study in Cell Metabolism showed Ca-AKG extended lifespan by 12% in female mice and reduced frailty by 46%. The mice didn't just live longer — they were healthier, with better fur quality, improved grip strength, and less tumor incidence
• Brain aging: A 2024 NUS study found that Ca-AKG restored memory-related brain functions in Alzheimer's disease models, suggesting neuroprotective potential

Dosage and Practical Considerations

Based on the clinical trials:

• Typical dose: 1,000 mg (1 gram) of calcium alpha-ketoglutarate daily
• Form: Timed/sustained-release capsules appear more effective than immediate-release
• Timing: Usually taken in the morning with food
• Safety: AKG has Generally Recognized As Safe (GRAS) status. No serious adverse events reported in clinical trials. Mild GI discomfort in some participants at higher doses.

Important caveats:

• The strongest human trial (Rejuvant) was retrospective and open-label
• The ABLE trial results are pending — this is the study that will make or break the case
• AKG is a metabolic intermediate, so effects may vary based on individual metabolic health
• Combination with vitamins (A for men, D for women) in the Rejuvant study makes it hard to isolate AKG's effect alone

How AKG Compares to Other Longevity Supplements

Supplement	Primary Mechanism	Human Evidence	Biological Age Reduction
Ca-AKG	Epigenetic + metabolic	Moderate (awaiting ABLE)	~8 years (one study)
NMN/NR	NAD+ precursor	Growing	Not yet measured
Rapamycin	mTOR inhibition	Limited (off-label)	Not yet measured
Metformin	AMPK activation	Strong (TAME trial ongoing)	~3 years (observational)
Spermidine	Autophagy induction	Moderate	Not yet measured

AKG stands out because it directly addresses epigenetic aging — the mechanism most closely tied to the biological clocks used to measure aging.

The Bottom Line

Alpha-ketoglutarate is one of the most promising longevity supplements to emerge from clinical research. An 8-year reduction in biological age is an extraordinary claim, and the evidence — while encouraging — still needs validation from the ABLE trial.

What makes AKG compelling is the convergence of evidence: solid animal data, plausible mechanisms targeting multiple hallmarks of aging, a strong safety profile, and early human results that are hard to ignore.

It's not a miracle pill. But if the ABLE trial confirms even half of what the preliminary data suggests, Ca-AKG could become a cornerstone of evidence-based longevity protocols.

---

Sources:

1. Demidenko, O. et al. (2021). "Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging." Aging, 13(24), 25390–25397. PMC8660611

2. Asadi Shahmirzadi, A. et al. (2020). "Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice." Cell Metabolism, 32(3), 447–456. DOI: 10.1016/j.cmet.2020.08.004

3. ABLE Study — ClinicalTrials.gov: NCT05706389

4. Su, Y. et al. (2023). "Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK." Aging Cell, 22(4). PMC10643463

5. Chin, R.M. et al. (2014). "The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR." Nature, 510, 397–401. DOI: 10.1038/nature13264

6. Kennedy, B.K. et al. (2024). "Ca-AKG restores memory-related brain functions in Alzheimer's disease models." National University of Singapore.